IP Library Granted Patent US 11,529,388
Granted Patent B2
US 11,529,388 · App. 16/870,035 · Granted Dec 20, 2022

Peptide-polynucleotide-hyaluronic acid nanoparticles and methods for polynucleotide transfection

Inventors: Samuel A. Wickline (Temple Terrace, FL); Hua Pan (Tampa, FL); Christine Thien-Nga Pham (St. Louis, MO); Huimin Yan (St. Louis, MO)
A61K38/16A61K9/51A61K31/7105A61K47/64A61P9/00A61P19/02C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,529,388
App. No.
16/870,035
Granted
Dec 20, 2022
Kind
B2
Abstract

The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Claims (17)

1. A pharmaceutical composition comprising a peptide-polynucleotide complex, the peptide-polynucleotide complex comprising:

a peptide;

a polynucleotide; and

hyaluronic acid;

wherein the peptide is non-lytic and capable of affecting the release of a polynucleotide from an endosome of a cell; and

wherein the peptide comprises SEQ ID NO: 1.

2. The composition of claim 1 , wherein the peptide-polynucleotide complex is about 10 nm to about 150 nm in diameter.

3. The composition of claim 2 , wherein the peptide-polynucleotide complex is about 10 nm to about 50 nm in diameter.

4. The composition of claim 1 , wherein the hyaluronic acid coats the peptide-polynucleotide complex.

5. The composition of claim 1 , wherein the hyaluronic acid is integrated into the peptide-polynucleotide complex.

6. The composition of claim 1 , wherein the polynucleotide is an RNA.

7. The composition of claim 1 , wherein the polynucleotide is an mRNA.

8. The composition of claim 1 , wherein the polynucleotide is a non-coding RNA capable of regulating or inhibiting the expression of a nucleic acid sequence.

9. The composition of claim 8 , wherein the non-coding RNA is an siRNA.

10. The composition of claim 8 , wherein the non-coding RNA is an miRNA.

11. The composition of claim 1 , wherein the peptide consists of SEQ ID NO: 1.

12. The composition of claim 1 , wherein the peptide-polynucleotide complex comprises a ratio of peptide:polynucleotide that is more than about 50:1 and less than about 200:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2024
From: WASHINGTON UNIVERSITY
To: UNITED STATES DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 068809/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2021
From: WICKLINE, SAMUEL A.; PAN, HUA
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 055176/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2021
From: PHAM, CHRISTINE THIEN-NGA; YAN, HUIMIN
To: WASHINGTON UNIVERSITY
Reel/Frame 055176/0973 →
Continuity (2)
Provisional Application 62845974 · May 10, 2019
Related Publication 20200353036A1 · Nov 12, 2020